Struma Ovarii with Papillary Thyroid Carcinoma and Metastasis to the Appendix: A Case Report and Literature Review

References

• Doganay M, Gungor T, Cavkaytar S, et al. Malignant struma ovarii with a focus of papillary thyroid cancer: a case report. Arch Gynecol Obstet. 2008;277(4):371–373. doi:10.1007/s00404-007-0466-6
   PubMed Web of Science ®Google Scholar
• Devaney K, Snyder R, Morris HJ, et al. Proliferative and histologically malignant struma ovarii: a clinicopathologic study of 54 cases. Int J Gynecol Pathol. 1993;12(4):333–343. doi:10.1097/00004347-199310000-00008
   PubMed Web of Science ®Google Scholar
• DeSimone CP, Lele SM, Modesitt SC. Malignant struma ovarii: a case report and analysis of cases reported in the literature with focus on survival and I131 therapy. Gynecol Oncol. 2003;89(3):543–548. doi:10.1016/S0090-8258(03)00141-0
   PubMed Web of Science ®Google Scholar
• Kabukcuoglu F, Baksu A, Yilmaz B, et al. Malignant struma ovarii. Pathol Oncol Res. 2002;8(2):145–147. doi:10.1007/BF03033726
   PubMedGoogle Scholar
• Roth LM, Talerman A. The enigma of struma ovarii. Pathology. 2007;39(1):139–146. doi:10.1080/00313020601123979
   PubMed Web of Science ®Google Scholar
• Siegel MR, Wolsky RJ, Alvarez EA, et al. Struma ovarii with atypical features and synchronous primary thyroid cancer: a case report and review of the literature. Arch Gynecol Obstet. 2019;300(6):1693–1707. doi:10.1007/s00404-019-05329-z
   PubMed Web of Science ®Google Scholar
• Marti JL, Clark VE, Harper H, et al. Optimal surgical management of well-differentiated thyroid cancer arising in struma ovarii: a series of 4 patients and a review of 53 reported cases. Thyroid. 2012;22(4):400–406. doi:10.1089/thy.2011.0162
   PubMed Web of Science ®Google Scholar
• Rose PG, Arafah B, Abdul-Karim FW. Malignant struma ovarii: recurrence and response to treatment monitored by thyroglobulin levels. Gynecol Oncol. 1998;70(3):425–427. doi:10.1006/gyno.1998.5056
   PubMed Web of Science ®Google Scholar
• Zhang R, Tian X, Luo Y, et al. Case report: recurrent malignant struma ovarii with hyperthyroidism and metastases, a rare case report and review of the literature. Pathol Oncol Res. 2022;28:1610221. doi:10.3389/pore.2022.1610221
   PubMed Web of Science ®Google Scholar
• Yücesoy G, Cakiroglu Y, Muezzinoglu B, et al. Malignant struma ovarii: a case report. J Korean Med Sci. 2010;25(2):327–329. doi:10.3346/jkms.2010.25.2.327
   PubMed Web of Science ®Google Scholar
• Cui Y, Yao J, Wang S, et al. The clinical and pathological characteristics of malignant struma ovarii: an analysis of 144 published patients. Front Oncol. 2021;11:645156.
   PubMed Web of Science ®Google Scholar
• Goffredo P, Sawka AM, Pura J, et al. Malignant struma ovarii: a population-level analysis of a large series of 68 patients. Thyroid. 2014;25(2):211–215. doi:10.1089/thy.2014.0328
   PubMed Web of Science ®Google Scholar
• Limaiem F, Bouraoui S. Follicular carcinoma arising from struma ovarii. A case report. Pathologica. 2020;112(4):224–228. doi:10.32074/1591-951X-122
   PubMed Web of Science ®Google Scholar
• Hatami M, Breining D, Owers RL, et al. Malignant struma ovarii--a case report and review of the literature. Gynecol Obstet Invest. 2008;65(2):104–107. doi:10.1159/000108654
   PubMed Web of Science ®Google Scholar
• Zhang X, Axiotis C. Thyroid-type carcinoma of struma ovarii. Arch Pathol Lab Med. 2010;134(5):786–791. doi:10.5858/134.5.786
   PubMed Web of Science ®Google Scholar
• Gonet A, Ślusarczyk R, Gąsior-Perczak D, et al. Papillary thyroid cancer in a struma ovarii in a 17-year-old nulliparous patient: a case report. Diagnostics. 2020;10(1). doi:10.3390/diagnostics10010045
   Web of Science ®Google Scholar
• Leite I, Cunha TM, Figueiredo JP, et al. Papillary carcinoma arising in struma ovarii versus ovarian metastasis from primary thyroid carcinoma: a case report and review of the literature. J Radiol Case Rep. 2013;7(10):24–33. doi:10.3941/jrcr.v7i10.1593
   PubMedGoogle Scholar
• Llueca A, Maazouzi Y, Herraiz JL, et al. Treatment and follow-up in an asymptomatic malignant struma ovarii: a case report. Int J Surg Case Rep. 2017;40:113–115. doi:10.1016/j.ijscr.2017.09.005
   PubMedGoogle Scholar
• Yazawa R, Yazawa H, Fukuda K, et al. Struma ovarii with massive ascites mimicking ovarian carcinoma treated with conservative laparoscopic surgery: a case report. Fukushima J Med Sci. 2023;69(1):37–43. doi:10.5387/fms.2022-30
   PubMed Web of Science ®Google Scholar
• Zalel Y, Seidman DS, Oren M, et al. Sonographic and clinical characteristics of struma ovarii. J Ultrasound Med. 2000;19(12):857–861. doi:10.7863/jum.2000.19.12.857
   PubMed Web of Science ®Google Scholar
• Matsuki M, Kaji Y, Matsuo M, et al. Struma ovarii: MRI findings. Br J Radiol. 2000;73(865):87–90. doi:10.1259/bjr.73.865.10721328
   PubMed Web of Science ®Google Scholar
• Park SB, Kim JK, Kim K-R, et al. Imaging findings of complications and unusual manifestations of ovarian teratomas. Radiographics. 2008;28(4):969–983. doi:10.1148/rg.284075069
   PubMed Web of Science ®Google Scholar
• Terayama N, Fujiwara S, Ueda S, et al. Malignant struma ovarii with thyroid-type papillary and poorly differentiated carcinoma: a case report J. Med Case Rep. 2022;16:1–5.
   Google Scholar
• Pyo J-S, Kim D-H, Yang J. Diagnostic value of CD56 immunohistochemistry in thyroid lesions. Int J Biol Markers. 2018;33(2):161–167. doi:10.1177/1724600817748538
   PubMed Web of Science ®Google Scholar
• Brenner W, Bohuslavizki KH, Wolf H, et al. Radiotherapy with iodine-131 in recurrent malignant struma ovarii. Eur J Nucl Med. 1996;23(1):91–94. doi:10.1007/BF01736995
   PubMedGoogle Scholar
• Muthusamy S, Azhar Sha S, Abdullah Suhaimi SN, et al. CD56 expression in benign and malignant thyroid lesions. Malays J Pathol. 2018;40(2):111–119.
   PubMed Web of Science ®Google Scholar
• Schlumberger M, Baudin E. Serum thyroglobulin determination in the follow-up of patients with differentiated thyroid carcinoma. Eur J Endocrinol. 1998;138(3):249–252. doi:10.1530/eje.0.1380249
   PubMed Web of Science ®Google Scholar
• Schmidt J, Derr V, Heinrich MC, et al. BRAF in papillary thyroid carcinoma of ovary (struma ovarii). Am J Surg Pathol. 2007;31(9):1337–1343. doi:10.1097/PAS.0b013e31802f5404
   PubMed Web of Science ®Google Scholar
• Yassa L, Sadow P, Marqusee E. Malignant struma ovarii. Nat Clin Pract Endocrinol Metab. 2008;4(8):469–472. doi:10.1038/ncpendmet0887
   PubMedGoogle Scholar
• Trovisco V, Vieira de Castro I, Soares P, et al. BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol. 2004;202(2):247–251. doi:10.1002/path.1511
   PubMed Web of Science ®Google Scholar
• Janszen EWM, Van Doorn HC, Ewing PC, et al. Malignant struma ovarii: good response after thyroidectomy and 131i ablation therapy. clinical medicine. Oncology. 2008;2:410.
   Google Scholar
• Li S, Kim H-S, Han I, et al. Clinical characteristics and survival outcomes of malignant struma ovarii confined to the ovary. BMC Cancer. 2021;21:21. doi:10.1186/s12885-020-07730-3
   PubMed Web of Science ®Google Scholar
• Zhu Y, Yanagimoto H, Yamamoto T, et al. Papillary thyroid cancer located in malignant struma ovarii with omentum metastasis: a case report and review of the literature. World J Surg Oncol. 2016;14:14. doi:10.1186/s12957-016-0767-y
   PubMed Web of Science ®Google Scholar